Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
Abstract Duchenne Muscular Dystrophy (DMD) is a lethal progressive muscle-wasting disease. New treatment strategies relying on DMD gene exon-skipping therapy have recently been approved and about 30% of patients could be amenable to exon 51, 53 or 45 skipping. We evaluated the spectrum of deletions...
Guardado en:
Autores principales: | Pablo Beckers, Jean-Hubert Caberg, Vinciane Dideberg, Tamara Dangouloff, Johan T. den Dunnen, Vincent Bours, Laurent Servais, François Boemer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/27dddf18d89948a6a54653f693dce78e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up.
por: Giorgia Coratti, et al.
Publicado: (2021) -
Novel Partial Exon 51 Deletion in the Duchenne Muscular Dystrophy Gene Identified via Whole Exome Sequencing and Long-Read Whole-Genome Sequencing
por: Qianqian Li, et al.
Publicado: (2021) -
Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium
por: François Boemer, et al.
Publicado: (2021) -
Evaluation of muscular changes by ultrasound Nakagami imaging in Duchenne muscular dystrophy
por: Wen-Chin Weng, et al.
Publicado: (2017) -
Computer task performance by subjects with Duchenne muscular dystrophy
por: Malheiros SRP, et al.
Publicado: (2015)